# 药品新兴市场 > 药品市场研究报告按产品类型（药品、医疗设备、诊断、biotechnology、生物仿制药）、按应用（治疗、诊断、预防、研发）、按疾病领域（癌症、心血管疾病、呼吸系统疾病、传染病、神经系统疾病）、按商业模式（品牌仿制药、生物仿制药、创新治疗、诊断和监测设备、合同研究和制造组织）、按分销渠道（医院和诊所、零售药店、在线市场、批发分销商、直销）以及按地区 - 预测到2035年 - **Forecast Period:** 2025 - 2035 - **CAGR:** 9.32% - **2024:** $ 359.1 Billion - **2025:** $ 392.57 Billion - **2035:** $ 957.02 Billion - **Key Players:** Companies such as Sun Pharmaceutical Industries Ltd (IN), Dr. Reddy's Laboratories Ltd (IN), Cipla Ltd (IN), Aurobindo Pharma Ltd (IN), Zydus Cadila (IN), Lupin Limited (IN), Sandoz (CH), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd (IL) are some of the major participants in the global pharmerging market. **Report ID:** MRFR/HC/27495-HCR · **Pages:** 128 · **Author:** Rahul Gotadki · **Last Updated:** May 15, 2026 **URL:** https://www.marketresearchfuture.com/reports/pharmerging-market-29204 --- ## Market Summary ## **Pharmerging Market Overview** As per MRFR analysis, the Pharmerging Market Size was estimated at 359.10 (USD Billion) in 2024. The Pharmerging Market Industry is expected to grow from 392.57 (USD Billion) in 2025 to 875.43 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 4.40% during the forecast period (2025 - 2034). ## **Key Pharmerging Market Trends Highlighted** Key market drivers in the Pharmerging Market include rising healthcare expenditure, increasing prevalence of chronic diseases, expanding access to healthcare services, and government initiatives to improve healthcare infrastructure. Opportunities to be explored or captured in this market include the development of affordable and accessible healthcare solutions, the expansion of telemedicine and digital health services, and the investment in research and development of new therapies. Trends in recent times in the Pharmerging Market include the rapid adoption of digital health technologies, the increasing focus on value-based healthcare, and the growing demand for personalized medicine. By addressing these key drivers, opportunities, and trends, stakeholders in the Pharmerging Market can effectively cater to the evolving needs of patients and healthcare providers, thereby driving growth and innovation in this dynamic market. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **Pharmerging Market Drivers** ### **Rising Demand for Healthcare Services in Emerging Economies** The growing population and increasing disposable income in emerging economies are driving the demand for healthcare services. This is leading to a surge in the demand for pharmaceuticals, medical devices, and other healthcare products and services. The Pharmerging Market Industry is well-positioned to meet this demand, as it offers a wide range of affordable and accessible healthcare products and services. The increasing demand for healthcare services in emerging economies is expected to continue to drive the growth of the Pharmerging Market Industry in the coming years. ### **Government Initiatives to Improve Healthcare Infrastructure** Many governments in emerging economies are implementing initiatives to improve healthcare infrastructure. This includes building new hospitals and clinics, upgrading existing facilities, and training healthcare professionals. These initiatives are creating a more favorable environment for the Pharmerging Market Industry, as they are making it easier for people to access healthcare services. The government initiatives to improve healthcare infrastructure are expected to continue to support the growth of the Pharmerging Market Industry. ### **Technological Advancements in the Pharmaceutical Industry** The pharmaceutical industry is constantly evolving, with new technologies being developed all the time. These technologies are leading to the development of new and more effective drugs, which is benefiting patients in emerging economies and can help the Pharmerging Market Industry. The technological advancements in the pharmaceutical industry are expected to continue to drive the growth of the Pharmerging Market Industry in the coming years. ## **Pharmerging Market Segment Insights** ### **Pharmerging Market Product Type Insights  ** The Pharmerging Market is segmented by product type into pharmaceuticals, medical devices, diagnostics, biotechnology, and generics. The pharmaceuticals segment is expected to hold the largest market share in 2023, accounting for over 50% of the global market. The medical devices segment is expected to be the fastest-growing segment, with a CAGR of over 10% during the forecast period. The growth of the pharmaceuticals segment is attributed to the increasing prevalence of chronic diseases, the rising adoption of biologics, and the growing demand for personalized medicine. The growth of the medical devices segment is attributed to the increasing demand for minimally invasive procedures, the growing adoption of robotic surgery, and the rising demand for home healthcare devices. The diagnostics segment is expected to grow at a steady pace during the forecast period. The growth of this segment is attributed to the increasing demand for early disease detection, the growing adoption of point-of-care testing, and the rising demand for personalized medicine. The biotechnology segment is expected to grow at a robust pace during the forecast period. The growth of this segment is attributed to the increasing demand for biopharmaceuticals, the growing adoption of gene therapy, and the rising demand for personalized medicine. The generics segment is expected to grow at a moderate pace during the forecast period. The growth of this segment is attributed to the increasing demand for affordable healthcare, the growing adoption of biosimilars, and the rising demand for generic drugs in emerging markets. The Pharmerging Market is expected to witness significant growth over the forecast period, driven by the increasing prevalence of chronic diseases, the growing demand for healthcare services, and the rising adoption of innovative technologies. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Pharmerging Market Application Insights  ** The Pharmerging Market is segmented by Application into Therapeutic, Diagnostic, Preventive, and Research and Development. The Therapeutic segment accounted for the largest market share in 2023, and is expected to continue to dominate the market over the forecast period. The growth of this segment can be attributed to the increasing prevalence of chronic diseases, such as cancer, diabetes, and cardiovascular diseases. The Diagnostic segment is also expected to witness significant growth over the forecast period, due to the rising demand for early and accurate diagnosis of diseases. The Preventive segment is expected to grow at a steady pace, driven by the increasing awareness of preventive healthcare measures. The Research and Development segment is expected to witness moderate growth over the forecast period, due to the increasing investment in the development of new and innovative drugs and therapies. ### **Pharmerging Market Disease Area Insights  ** The Pharmerging Market segmentation by Disease Area comprises Cancer, Cardiovascular Diseases, Respiratory Diseases, Infectious Diseases, and Neurological Disorders. Among these, Cancer accounted for the largest revenue share in 2023, owing to the rising prevalence of various types of cancer and the increasing adoption of advanced treatment modalities. The Cardiovascular Diseases segment is expected to exhibit a significant growth rate during the forecast period, driven by the growing burden of cardiovascular diseases and the increasing demand for effective treatment options. The Respiratory Diseases segment is also poised for growth, driven by the rising prevalence of respiratory diseases such as asthma and [chronic obstructive pulmonary disease](../../../reports/chronic-obstructive-pulmonary-disease-copd-market-1612) (COPD). The Infectious Diseases segment is expected to witness steady growth, fueled by the increasing incidence of infectious diseases and the need for effective vaccines and therapeutics. The Neurological Disorders segment is anticipated to grow at a moderate pace, driven by the rising prevalence of neurological disorders such as Alzheimer's disease and Parkinson's disease. ### **Pharmerging Market Business Model Insights ** The Pharmerging Market is segmented based on business model into branded generics, biosimilars, innovative therapeutics, diagnostics and monitoring devices, and contract research and manufacturing organizations. Among these segments, branded generics are expected to hold the largest market share in 2023, owing to their lower cost and increased accessibility compared to their branded counterparts. [Biosimilars](../../../reports/biosimilars-market-1329) are also expected to witness significant growth, driven by the increasing adoption of biologics and the expiration of patents for several blockbuster drugs. Innovative therapeutics, which include novel drugs and therapies, are expected to contribute to the growth of the Pharmerging Market due to their potential to address unmet medical needs. Diagnostics and monitoring devices are also expected to witness steady growth, driven by the increasing demand for early disease detection and monitoring. Contract research and manufacturing organizations are expected to benefit from the growing outsourcing trend in the pharmaceutical industry. ### **Pharmerging Market Distribution Channel Insights  ** The distribution channel segment plays a critical role in the Pharmerging Market, influencing the accessibility and availability of products to end-users. Hospitals and clinics accounted for the largest revenue share in 2023, driven by the high volume of patient visits and the need for specialized medications. Retail pharmacies also hold a significant market share, offering convenience and accessibility to consumers. Online marketplaces are gaining traction, particularly for chronic medications and over-the-counter products, as they provide a wider selection and competitive pricing. Wholesale distributors facilitate the distribution of products from manufacturers to various distribution channels, ensuring efficient and cost-effective delivery. Direct-to-consumer channels, including e-commerce platforms and subscription services, are emerging as viable options, offering personalized and tailored healthcare experiences. ### **Pharmerging Market Regional Insights  ** The regional segmentation of the Pharmerging Market comprises North America, Europe, APAC, South America, and MEA. Among these regions, North America held the largest market share in 2023, accounting for around 35.8% of the global revenue. The growth in this region can be attributed to the presence of well-established pharmaceutical companies, favorable government policies, and high healthcare expenditure. Europe is another significant region in the Pharmerging Market, with a market share of approximately 28.4% in 2023. The region's growth is driven by factors such as increasing healthcare awareness, rising demand for innovative treatments, and a strong healthcare infrastructure. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Pharmerging Market Key Players And Competitive Insights:** Major players in Pharmerging Market industry are constantly striving to gain a competitive edge by investing in research and development, expanding their product portfolio, and acquiring smaller players. Leading Pharmerging Market players are focusing on developing innovative drugs and therapies to address unmet medical needs and cater to the growing demand for healthcare solutions in emerging markets. The Pharmerging Market development landscape is characterized by strategic partnerships, collaborations, and joint ventures between key players to leverage expertise, share resources, and expand market reach. The competitive landscape is expected to remain dynamic as new entrants and established players continue to vie for market share. Novartis, a leading pharmaceutical company, holds a strong position in the Pharmerging Market industry. The company's focus on developing innovative drugs and expanding its presence in emerging markets has contributed to its success. Novartis has a diversified product portfolio covering various therapeutic areas, including cardiovascular diseases, oncology, neuroscience, and respiratory diseases. The company's commitment to research and development has resulted in the development of blockbuster drugs such as Gleevec and Cosentyx, which have gained significant market share in Pharmerging markets. Pfizer, another major player in the Pharmerging Market industry, is known for its strong vaccine portfolio and presence in emerging markets. The company has been actively expanding its operations in these markets through strategic acquisitions and partnerships. Pfizer's vaccine portfolio includes Prevnar 13, which is used to prevent pneumococcal diseases, and Comirnaty, the COVID-19 vaccine developed in collaboration with BioNTech. The company's focus on expanding access to essential medicines and vaccines in emerging markets has contributed to its strong position in the Pharmerging Market industry. ## **Key Companies in the Pharmerging Market Include:** - Biocon - Cipla - Alembic Pharmaceuticals - Hetero Labs - Reddy's Laboratories - Lupin - **[Glenmark Pharmaceuticals](https://glenmarkpharma.com/)** - Torrent Pharmaceuticals - Intas Pharmaceuticals - Piramal Enterprises - Cadila Healthcare - USV - Aurobindo Pharma - Zydus Cadila - Sun Pharmaceutical Industries ## Pharmerging Market Industry Developments - **Q1 2024: Novartis’s slippage on the league table in 2024 reflects the spin-out of its Sandoz generics and biosimilars business in October 2023. Its core pharmaceutical business performed strongly, however, with the company reporting 12% growth of net pharma sales to $50.3bn.** Novartis completed the spin-out of its Sandoz generics and biosimilars business in October 2023, focusing on its core pharmaceutical segment which reported 12% net sales growth to $50.3 billion in 2024. - **Q1 2024: CEO Vas Narasimhan believes CDK4/6 inhibitor breast cancer drug Kisqali (ribociclib) will help drive ongoing growth and could eventually reach annual sales of $8bn. Kisqali sales grew by 49% to $3bn in 2024.** Novartis reported a 49% increase in sales of its breast cancer drug Kisqali (ribociclib), reaching $3 billion in 2024, with expectations for continued growth. - **Q1 2024: BMS is implementing cost-cutting plans with recently appointed CEO Christopher Boerner adding $2bn in cuts in 2025–2027 to a $1.5bn plan already in place since last year.** Bristol Myers Squibb announced a new $2 billion cost-cutting initiative for 2025–2027 under CEO Christopher Boerner, supplementing an existing $1.5 billion plan. - **Q1 2024: He highlighted 'a multitude of important data readouts over the next 24 months with the potential to launch 10 or more new medicines and pursue over 30 indication expansion opportunities over the next five years.'** Bristol Myers Squibb expects to launch 10 or more new medicines and pursue over 30 indication expansions in the next five years, based on upcoming clinical data readouts. ## **Pharmerging Market Segmentation Insights** ### **Pharmerging Market Product Type Outlook** - Pharmaceuticals - Medical Devices - Diagnostics - Biotechnology - Generics ### **Pharmerging Market Application Outlook** - Therapeutic - Diagnostic - Preventive - Research and Development ### **Pharmerging Market Disease Area Outlook** - Cancer - Cardiovascular Diseases - Respiratory Diseases - Infectious Diseases - Neurological Disorders ### **Pharmerging Market Business Model Outlook** - Branded Generics - Biosimilars - Innovative Therapeutics - Diagnostics and Monitoring Devices - Contract Research and Manufacturing Organizations ### **Pharmerging Market Distribution Channel Outlook** - Hospitals and Clinics - Retail Pharmacies - Online Marketplaces - Wholesale Distributors - Direct-to-Consumer ### **Pharmerging Market Regional Outlook** - North America - Europe - South America - Asia Pacific - Middle East and Africa ## Market Drivers ### 老龄化人口 人口老龄化的趋势是新兴市场制药行业的一个关键驱动因素。随着预期寿命的增加，慢性疾病的患病率也相应上升，从而对药品的需求加大。报告显示，到2030年，60岁及以上的人口将超过10亿，尤其是在新兴经济体中。这一人口趋势可能为制药公司创造出大量机会，以开发和营销针对老年人需求的产品。因此，新兴市场制药行业在适应这一不断扩大的人口的医疗保健需求时，正处于增长的有利位置。 ### 增加医疗支出 新兴市场正在各个地区见证医疗支出显著增加。各国政府和私营部门正在将更多资源分配给医疗保健，这一趋势受到收入增长和中产阶级扩大的推动。例如，某些新兴市场的医疗支出预计在未来几年将以超过10%的年复合增长率增长。这一投资激增可能会改善药物和医疗服务的可及性，从而扩大制药产品的市场。因此，新兴市场预计将受益于改善的医疗基础设施和对创新疗法的需求增加。 ### 分销渠道的扩展 新兴市场正在经历分销渠道的转型，这增强了药品的可及性。电子商务和数字健康平台的兴起正在促进药物向偏远地区的分发，从而使服务不足的人群受益。此外，制药公司与当地分销商之间的合作变得越来越普遍，从而实现了更高效的供应链。这种分销渠道的扩展可能会改善市场渗透率，并增加基本药物的可用性。因此，新兴市场将从这些进步中受益，最终使患者和医疗服务提供者都受益。 ### 政府倡议和政策 政府的举措和政策在塑造新兴制药市场中发挥着关键作用。许多政府正在实施旨在改善医疗保健可及性和可负担性的政策，这直接影响到制药行业。例如，促进仿制药和降低药品价格的举措正变得越来越普遍。这些政策旨在增强竞争，确保基本药物能够更广泛地提供给人群。此外，监管框架正在不断发展，以促进新药的更快审批流程，从而鼓励创新。这些支持性的政府行动可能会为新兴制药市场的增长创造有利环境。 ### 慢性疾病发病率上升 新兴市场受到慢性疾病（如糖尿病、心血管疾病和呼吸系统疾病）发病率上升的显著影响。数据显示，这些疾病的流行率正在以惊人的速度上升，尤其是在生活方式变化和城市化普遍存在的新兴市场。例如，世界卫生组织报告称，到2030年，非传染性疾病预计将占所有死亡人数的73%。这一趋势可能会推动对创新治疗和药物的需求，从而推动新兴市场的增长，以应对受影响人群的紧迫医疗需求。 ## Future Outlook 新兴市场预计将在2024年至2035年间以9.32%的年复合增长率增长，推动因素包括医疗保健获取的增加、慢性疾病的上升以及创新药物的发展。 **New opportunities:** - 在新兴市场扩展远程医疗服务。 到2035年，药品新兴市场预计将成为全球医疗保健中的一个关键领域。 ## Segment Insights ### 按产品类型：制药（最大）与生物技术（增长最快） 在新兴市场中，产品类型的划分显示制药产品是最大的细分市场，占据了整体市场份额的显著部分。医疗设备和诊断产品也贡献了可观的份额，但紧随其后的是仿制药，其渗透率有所提高。生物技术虽然在这些细分市场中所占份额较小，但随着该领域创新的加速，其重要性正在迅速提升。 制药：成熟（主导）与生物技术：创新（新兴） 制药行业作为主导者，代表了一个成熟的细分市场，拥有广泛的产品阵容，以满足各种治疗需求。该细分市场依赖于强大的研发能力，确保新药物的持续供应。相比之下，生物技术则展现出市场中一个充满活力和新兴的方面。它以基因治疗和单克隆抗体等尖端技术为特征，承诺带来革命性的进展。该领域的增长得益于持续的创新以及生物技术公司与研究机构之间的合作，使其成为解决未满足的医疗需求的关键参与者。 ### 按应用：治疗（最大）与诊断（增长最快） 在制药市场中，应用领域主要由治疗解决方案驱动，由于慢性疾病的日益普遍和对先进治疗选择的需求不断增长，治疗领域占据了最大的市场份额。治疗领域涵盖了广泛的治疗方法，确保其在其他应用中保持主导地位。诊断应用也在获得关注，成为增长最快的领域，因为技术的进步和医疗投资的增加提升了多种疾病状态下的诊断能力。 治疗性（主导）与诊断性（新兴） 治疗应用在新兴制药市场中占据主导地位，受到药物开发创新和各种适应症治疗选择扩展的推动。它通常包括旨在治疗从轻度到重度疾病的处方药和生物制剂。相比之下，诊断应用虽然目前是一个新兴领域，但由于行业向预防性医疗和个性化医学的转变，正在经历强劲的增长。技术进步，如即时检测和先进成像方法，显著提高了诊断的准确性和效率，使其成为整体医疗保健领域的关键参与者。 ### 按疾病领域：癌症（最大）与心血管疾病（增长最快） 新兴市场在其疾病领域细分中显示出多样化的分布。癌症继续主导市场份额，凭借其全面的治疗途径和日益增长的发病率。心血管疾病虽然在市场份额上落后，但由于发病率的增加和创新疗法的发展，正在迅速崛起，近年来显示出显著的前景。这些因素突显了对在医疗保健优先事项中获得大量关注的疾病的关注转变。 增长趋势表明疾病领域的分化，癌症因强大的资金和研究倡议而优先。相反，心血管疾病正在见证研究活动和制药开发的激增，这受到导致心脏相关疾病的生活方式上升的推动。预防和治疗措施的持续进展在刺激这些细分市场的增长中也发挥着至关重要的作用。 癌症（主导）与神经系统疾病（新兴） 癌症在新兴市场中被确立为主导疾病领域，这得益于广泛的研究和创新的治疗方式，包括免疫疗法和精准医学。制药行业在癌症治疗药物上进行了大量投资，以适应日益增长的患者群体。相比之下，神经系统疾病被视为一个新兴领域，因对阿尔茨海默病和帕金森病等疾病的认识和诊断增加而获得关注。老年人口的增加和对心理健康改善的推动是神经治疗的关键驱动因素。该领域的特点是未满足的医疗需求，为制药公司探索新型治疗干预提供了广阔的机会。 ### 按商业模式：品牌仿制药（最大）与生物类似药（增长最快） 在新兴市场中，市场份额在商业模式之间的分布显示出品牌仿制药的强大存在，目前由于其在医疗专业人士和患者中的广泛接受，品牌仿制药主导了这一细分市场。这一优势得到了生物类似药日益被认可和采用的支持，生物类似药作为传统生物治疗的经济替代品正在获得关注。随着市场的发展，这些细分领域预计将在竞争动态中更加激烈地参与，因为医疗保健领域正向可负担性和可及性转变。 新兴市场的增长趋势受到对可负担医疗解决方案需求上升的推动，品牌仿制药受益于高销量和在成熟及新兴经济体中的广泛使用。同时，生物技术的快速进步正在推动生物类似药细分市场的发展，为创新和差异化创造了肥沃的土壤。慢性疾病发生率的增加和支持性的监管环境等因素进一步加速了增长，突显了对这些商业模式进行战略投资的重要性。 品牌仿制药（主导）与生物类似药（新兴） 品牌仿制药在新兴市场中占据主导地位，具有良好的市场存在感和强大的品牌认知度。这些产品为医疗系统提供了显著的价值，因为它们提供了经济实惠的治疗选择，而不牺牲质量。品牌仿制药被广泛接受，源于其有效满足患者需求的能力，同时降低整体医疗成本。另一方面，生物类似药被视为一个新兴领域，提供与现有生物制剂相当的疗效和安全性，但成本却低得多。生物类似药市场正在迅速发展，受到对研发的投资增加以及对生物治疗在治疗方案中日益重视的推动。这两个领域在塑造医疗未来方面发挥着至关重要的作用，增强了患者获得必要治疗的机会。 ### 按分销渠道：医院和诊所（最大）与在线市场（增长最快） 在新兴市场中，分销渠道正在多样化，医院和诊所的市场份额领先。这个细分市场至关重要，因为它提供了大量的医疗服务，并且是药物分发的主要途径。紧随其后的是零售药店和批发分销商，由于其广泛的可用性和可及性，拥有相当大的市场存在。同时，在线市场正在迅速扩展，随着消费者越来越寻求便利来获取药物和健康产品，获得了越来越多的关注。 医院和诊所（主导）与在线市场（新兴） 医院和诊所是新兴市场中主要的分销渠道，以其综合医疗服务为特征，包括初级护理、专科咨询和必要的治疗。它们作为药物分销的关键点，确保药物直接送达患者。相反，在线市场正在成为一个重要的参与者，这一变化受到技术影响下消费者习惯的改变。这些平台提供便利和可及性，使患者更容易在家中购买药物。这一日益增长的趋势反映了医疗保健领域向电子商务的转变，为供应链管理和客户参与的创新铺平了道路。 ## Regional Market Share Analysis ### 北美：制药创新领袖 北美仍然是制药新兴市场领域最大的市场，约占全球市场份额的40%。主要增长驱动因素包括先进的医疗基础设施、对仿制药的需求增加以及支持性的监管框架。该地区对创新和研究的关注进一步受到政府旨在提高药物可及性和可负担性的倡议的推动。美国是该地区的领先国家，加拿大也做出了重要贡献。像迈兰公司（Mylan N.V.）和梯瓦制药工业有限公司（Teva Pharmaceutical Industries Ltd）这样的主要参与者非常突出，同时印度制药公司如太阳制药（Sun Pharmaceutical）和德鲁迪实验室（Dr. Reddy's Laboratories）也有强大的存在。竞争格局的特点是战略合作伙伴关系和旨在扩大市场覆盖范围的合并。 ### 欧洲：多样化的市场动态 欧洲是制药新兴市场领域第二大市场，约占全球份额的30%。该地区的增长受到老龄化人口、医疗支出增加和慢性疾病患病率上升的推动。监管机构积极促进仿制药的使用，这预计将进一步推动市场动态和基本药物的可及性。主要国家包括德国、法国和英国，竞争格局中既有成熟企业也有新兴参与者。像桑多兹（Sandoz）和西普拉（Cipla）这样的公司正在取得显著进展，而当地公司也在创新以满足特定的区域需求。强有力的监管框架确保了质量和安全，增强了消费者对制药产品的信任。 ### 亚太地区：快速增长与扩张 亚太地区在制药新兴市场中正经历快速增长，约占全球份额的20%。主要驱动因素包括医疗投资增加、中产阶级增长和健康问题意识的提高。印度和中国等国处于前沿，政府政策支持旨在增强制药制造和分销能力。印度是一个重要参与者，像阿尤尔宾多制药（Aurobindo Pharma）和齐鲁制药（Zydus Cadila）等公司在前进。竞争格局以本地和国际公司混合为特征，重点关注可负担的仿制药和生物类似药。该地区多样化的人口和不同的医疗需求为市场参与者带来了挑战和机遇，推动了创新和量身定制的解决方案。 ### 中东和非洲：新兴市场潜力 中东和非洲（MEA）地区正在成为制药新兴市场领域的潜在增长市场，约占全球份额的10%。主要增长驱动因素包括医疗投资增加、疾病患病率上升以及旨在改善医疗可及性的政府倡议。该地区的监管环境多样化，这既可以挑战制药公司的市场准入，也可以促进市场准入。主要国家包括南非和阿联酋，当地公司越来越多地与国际参与者合作。像卢平有限公司（Lupin Limited）这样的公司正在扩大其市场足迹，而竞争格局也在不断演变，新进入者专注于仿制药和创新疗法。该地区独特的挑战，如不同的医疗基础设施，需要量身定制的成功策略。 ## Competitive Benchmarking 新兴市场（Pharmerging Market）以其动态的竞争格局为特征，目前正经历着强劲的增长，推动因素包括日益增长的医疗需求、可支配收入的增加以及药物获取的扩大。主要参与者如印度的太阳制药工业有限公司（Sun Pharmaceutical Industries Ltd）、印度的德鲁迪实验室有限公司（Dr. Reddy's Laboratories Ltd）和印度的西普拉有限公司（Cipla Ltd）正通过创新和区域扩展来战略性地定位自己。太阳制药工业有限公司专注于通过研发来增强其产品组合，而德鲁迪实验室有限公司则强调战略合作伙伴关系以增强其市场存在感。西普拉有限公司积极推进数字化转型举措，以简化运营并改善患者参与度，共同塑造了一个优先考虑适应性和响应市场需求的竞争环境。 这些公司采用的商业策略包括本地化生产和优化供应链，以提高效率并降低成本。市场结构似乎适度分散，多个参与者争夺市场份额。然而，这些主要参与者的集体影响力是显著的，因为他们推动创新并设定行业标准，从而塑造新兴市场的竞争动态。 2025年8月，太阳制药工业有限公司宣布与一家领先的生物技术公司建立战略合作关系，以开发慢性疾病的新疗法。这一合作关系可能会增强太阳的研究能力并扩展其治疗产品，令公司在日益关注创新解决方案的竞争格局中处于有利位置。 2025年9月，德鲁迪实验室有限公司推出了一种新的生物仿制药，旨在治疗自身免疫性疾病。这一推出不仅使德鲁迪的产品组合多样化，还反映了其解决未满足医疗需求的承诺，可能会增加其在生物仿制药领域的市场份额。 2025年7月，西普拉有限公司推出了一个数字健康平台，旨在改善患者对药物治疗方案的依从性。这一举措强调了西普拉将技术融入医疗服务的重点，这可能会改善患者结果并巩固其在以患者为中心的解决方案中的领导地位。 截至2025年10月，新兴市场的当前竞争趋势越来越多地受到数字化、可持续性和人工智能整合的定义。战略联盟变得至关重要，因为公司寻求利用互补优势来增强其市场地位。展望未来，竞争差异化可能会从传统的基于价格的竞争演变为关注创新、技术进步和供应链可靠性，反映出行业向可持续和以患者为中心的方法的更广泛转变。 ## Recent News & Developments - **2024年第一季度：诺华在2024年的排名下滑反映了其在2023年10月剥离的Sandoz仿制药和生物类似药业务。然而，其核心制药业务表现强劲，公司报告净制药销售额增长12%，达到503亿美元。** 诺华在2023年10月完成了其Sandoz仿制药和生物类似药业务的剥离，专注于其核心制药部门，该部门在2024年报告净销售额增长12%，达到503亿美元。 - **2024年第一季度：首席执行官瓦斯·纳拉西曼相信CDK4/6抑制剂乳腺癌药物Kisqali（利博西克）将推动持续增长，并可能最终达到80亿美元的年销售额。Kisqali的销售在2024年增长了49%，达到30亿美元。** 诺华报告其乳腺癌药物Kisqali（利博西克）的销售增长49%，在2024年达到30亿美元，并预计将继续增长。 - **2024年第一季度：BMS正在实施成本削减计划，新任首席执行官克里斯托弗·博尔纳在2025-2027年增加了20亿美元的削减，补充了自去年以来已实施的15亿美元计划。** 布里斯托尔-迈尔斯·斯奎布宣布在首席执行官克里斯托弗·博尔纳的领导下，为2025-2027年推出新的20亿美元成本削减计划，补充现有的15亿美元计划。 - **2024年第一季度：他强调“在接下来的24个月内将有大量重要数据发布，可能推出10种或更多新药，并在未来五年内追求超过30个适应症扩展机会。”** 布里斯托尔-迈尔斯·斯奎布预计将在未来五年内推出10种或更多新药，并在接下来的临床数据发布的基础上追求超过30个适应症扩展。 ## Report Scope | 2024年市场规模 | 359.1（十亿美元） | | --- | --- | | 2025年市场规模 | 392.57（十亿美元） | | 2035年市场规模 | 957.02（十亿美元） | | 年复合增长率（CAGR） | 9.32%（2024 - 2035） | | 报告覆盖范围 | 收入预测、竞争格局、增长因素和趋势 | | 基准年 | 2024 | | 市场预测期 | 2025 - 2035 | | 历史数据 | 2019 - 2024 | | 市场预测单位 | 十亿美元 | | 关键公司简介 | 市场分析进行中 | | 覆盖的细分市场 | 市场细分分析进行中 | | 关键市场机会 | 新兴技术和监管变化推动Pharmerging市场的增长机会。 | | 关键市场动态 | 对可负担医疗保健的需求上升推动Pharmerging市场的创新和竞争。 | | 覆盖的国家 | 北美、欧洲、亚太、南美、中东和非洲 | ## Frequently Asked Questions **Q: 截至2024年，Pharmerging市场的当前估值是多少？** A: 2024年，制药新兴市场的估值为3591亿美元。 **Q: 到2035年，Pharmerging市场的预计市场规模是多少？** A: 到2035年，制药新兴市场预计将达到9570.2亿美元。 **Q: 在2025年至2035年的预测期内，Pharmerging市场的预期CAGR是多少？** A: 在2025年至2035年的预测期内，制药新兴市场的预期CAGR为9.32%。 **Q: 在制药新兴市场中，哪些公司被视为关键参与者？** A: 在新兴制药市场的主要参与者包括阳光制药工业有限公司、德鲁迪实验室有限公司和西普拉有限公司等。 **Q: 在新兴制药市场中主要的产品细分是什么？** A: 主要产品细分包括制药、医疗设备、诊断、生物技术和仿制药。 **Q: 在新兴制药市场中，治疗应用的市场与诊断应用的市场相比如何？** A: 治疗应用领域预计将从1200亿美元增长到3200亿美元，而诊断应用领域预计将从800亿美元增长到2000亿美元。 **Q: 在新兴市场中，癌症治疗领域的预计增长是多少？** A: 预计到2035年，癌症治疗领域将从750亿美元增长到2000亿美元。 **Q: 在新兴市场中，哪些分销渠道是普遍存在的？** A: 普遍的分销渠道包括医院和诊所、零售药店、在线市场、批发分销商和直销给消费者。 **Q: 在新兴市场中，哪些商业模式正在出现？** A: 新兴商业模式包括品牌仿制药、生物类似药、创新疗法以及合同研究和制造组织。 **Q: 神经系统疾病市场与其他疾病领域在新兴市场中的比较如何？** A: 神经系统疾病市场预计将从741亿美元增长到2070.2亿美元，显示出与其他疾病领域相比的强劲增长。 --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/pharmerging-market-29204*